Key statistics
On Friday, LSL Pharma Group Inc (LSL:CVE) closed at 0.52, -7.14% below its 52-week high of 0.56, set on Jan 29, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.52 |
|---|---|
| High | 0.52 |
| Low | 0.52 |
| Bid | 0.52 |
| Offer | 0.530 |
| Previous close | 0.50 |
| Average volume | 56.08k |
|---|---|
| Shares outstanding | 126.73m |
| Free float | 95.71m |
| P/E (TTM) | 21.66 |
| Market cap | 65.90m CAD |
| EPS (TTM) | 0.024 CAD |
Data delayed at least 15 minutes, as of Feb 06 2026 18:56 GMT.
More ▼
- LSL PHARMA GROUP GRANTS STOCK OPTIONS
- LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES
- LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING
- LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC
- LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M
- LSL PHARMA GROUP REPORTS FOURTH CONSECUTIVE RECORD QUARTERLY REVENUES AND Q3 2025 FINANCIAL RESULTS
- LSL PHARMA GROUP COMPLETES THE ACQUISITION OF LABORATOIRE DU-VAR INC.
More ▼
